Gold vs US Dollar

Register for real-time alerts, custom portfolio, and market movers

Get Started

Home
Investing
Stocks
UK
LSE
Ultrasis (ULT) Share Price

ULT Ultrasis

0.095

0.00 (0.00%)

Last Updated: 01:00:00

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ultrasis	LSE:ULT	London	Ordinary Share	GB0001494979	ORD 0.1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.00%	0.095	0.00	01:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
				-

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
-	O	0	0.095	GBX

Ultrasis (ULT) Latest News

Real-Time news about Ultrasis (London Stock Exchange): 0 recent articles

More Ultrasis News

Ultrasis Investors Ultrasis Takeover Rumours

Ultrasis (ULT) Discussions and Chat

Ultrasis Forums and Chat

Date	Time	Title	Posts
18/4/2024	22:01	Ultrasis/Screenetics/u2 Interactive Health Care.	17,349
03/1/2024	18:15	Ultrasis - Interactive Healthcare	35,338
20/1/2020	10:58	Ultrasis/Screenetics/u2 Interactive Health Care.	1,131
19/1/2020	11:54	Where is Ultrasis Heading?	2,740
18/1/2020	21:48	Pab, the enemy within	64

Add a New Thread

Ultrasis (ULT) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Ultrasis trades in real-time

Ultrasis (ULT) Top Chat Posts

Top Posts
Posted at 29/3/2024 14:31 by woollworth Humph its time for blood letting, when can you fit her 🐖 in? Got an order for 200 trotter at good price, let me know a place and pigin time please 😀 Read Full Thread Reply
Posted at 04/3/2024 15:14 by woollworth Humph the 🐖 wake, sent invites to Katie Price, Chainlink, derwent 1 3 and 5, all the ultrasis investors, staff John Smith, Paul Bell and Gerry Malone, Nigel Brabbins all in the seychelles living off our dosh. Read Full Thread Reply
Posted at 07/12/2023 17:19 by woollworth Yes humph just noticed your reply, forgot to say Katy price apologies lol. Read Full Thread Reply
Posted at 27/9/2023 12:14 by 2pigshit How can a company of this size and a few hundred thousand turnover be worth 25 million quid and what percentage do they knock off the price to keep boots and the like interested.this stock is ok for a quick profit or loss but no worth keeping to long that's why you are losing you trousers umpy by the way I heard you were on holiday in Australia at present you are in SIDNEY. You dirty little man Read Full Thread Reply
Posted at 27/8/2023 00:14 by woollworth Dooms it pig1,2,3 derwent, derwent4, chainman, Katie Price, all for the price of one lol. PS 🐖 stink ;) Read Full Thread Reply
Posted at 25/8/2023 23:28 by doomsday_man Lots of posts here considering this company has not existed for years. It must be a private messaging service. If I am wrong, when did ULT last make a profit?. Read Full Thread Reply
Posted at 26/7/2023 22:03 by humphries1 Hi wooly this from ELRAMPO.thomascromwell Premium MemberPosts: 398Price: 13.75No OpinionRE: Opti over 400%Today 08:29It is good to see Opti romp away, a little disconcerting that I am not a shareholder. I firmly believe that Croda will be selling Skin's lysate into the cosmetic market before the commercial roll-out of sweetbiotix, the market is huge for both products.-------------My responseThomas,I think SOH has expressed significant revenues from SweetBiotix for 2025. There is hope for at least one soft launch with one of the named partners for this year. This will be via a second r third tier product rather than a blue-label first-tier product for obvious reasons and will be limited to a small territory. I suspect this will be to avoid potential lousy PR, such as Irnon Brew had when AG Bar changed its sweetener.The clinical trials for Croda won't commence until November and will continue for 3-4 months. It remains uncertain as to how fast Croda will enter the launch phase. I anticipate that Sederma will supply their customers with the lysate as the scientific papers are being prepared since they are vital in making the "specific claims - enhancements" that distinguish the new products from the present ones.I think there will hardly be any requirement for a soft launch of any new skincare or cosmetic products once the scientific papers endorsing sales literature are accessible. It remains to be seen if the VIPs launch first or ROW simultaneously.I have suggested this be a line of enquiry for the future so we have an idea of the timeline. It's a tad early at this stage.Probably, SBTX will quicker generate "blue touchpaper" revenue than SweetBiotix, due in part to the regulatory obstacles faced by SweetBiotix as a consumable product, which requires much more preparation and care than Skincare topicals; on the other hand, does not face the same restrictive hurdles.SweetBiotix has an extensive range of products as the intel inside, so when traction does build, it could be highly significant. Ultimately, it will come down to sales volumes and tiered royalties.Build your positions and sit back! Read Full Thread Reply
Posted at 24/7/2023 13:13 by humphries1 Hi wooly this from ELRAMPO..Peeps,TBC, I was not suggesting SOH misled investors or me with his comments in 2018 - my point was one of perception from discussions with investors and comments on forums, etc. Of course, SOH will have been privy to much of what the potential partners were strategising regarding taste, storage testing, etc. The fact CC was sat of SweetBiotix for two years must have frustrated SOH no end. This is the price with Fledglings partnering with global corps; it is a risk that needs to be taken when ambitions are so great. There's not a lot you can do about it.Ref AQSEI spoke to SOH about AQSE just last week. He made an astonishing comment which I pushed back on. It concerned me because it suggested he does not see the problem as we investors do. I also explained that iWeb does not provide access via SIPP or ISA. II will provide access via their trading platform, but not in a SIPP.For example, I mentioned that I made added to my PBX in-specie position, but it showed a 39% loss due to a significant difference between BID and OFFER prices. I reminded him of my concern that this would be a problem and the most likely reason for the share price destruction. The SOH compared it to AIM suggesting there is not much difference in this regard. I explained that it was not similar - I pointed out that the spread of stocks in my AIM portfolio is usually about 5-10%, not the much larger 40-50%. Read Full Thread Reply
Posted at 19/7/2023 08:31 by humphries1 Hi wooly news on SEEETBIOTIX..?We are delighted to have John Wood, CEO at Harland & Wolff #HARL present at our next IR Webinar on July 25 at 5.55 pm. To attend please register here.Less Ads, More Data, More Tools Register for FREE Share PricesOptiBiotix Health Share PriceOptiBiotix Health Share Regulatory NewsSweetBiotix® overview?OptiBiotix Health Regulatory News (OPTI)?OPTI SharePrice?OPTI ShareNews?OPTI ShareChat3?OPTI ShareTrades13?OPTILive RNS1OptiBiotix Health Information ?Buy OPTI Shares?Add OPTI to Watchlist?Add OPTI to Alert Share Price Information for OptiBiotix Health (OPTI)? Share Price is delayed by 15 minutesGet Live DataShare Price:8.25Bid:8.00Ask:8.50Change:0.90 (12.24%) Spread: 0.50 (6.25%)Open: 7.50High: 8.25Low: 7.50Prev. Close: 7.35?Last checked at 08:30:53SweetBiotix® overviewToday 07:00RNS Number : 4299GOptiBiotix Health PLC19 July 2023 OptiBiotix Health plc("OptiBiotix" or the "Company" or the "Group") SweetBiotix® overview OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, provides an overview of its SweetBiotix® product range in the light of recent news interest in sweeteners. Market needThe sugar substitutes market is projected to grow from USD 18.8 billion in 2023 to USD 24.3 billion by 2028, growing at a compound annual growth rate of 5.2% (Research and Markets, April 2023). Sugar substitutes taste sweet but do not contain sugar. They have fewer calories than sugar or no calories at all and fall into three categories: artificial sweeteners (e.g aspartame, sucralose, saccharin), sugar alcohols (e.g. erythritol, xylitol, sorbitol) and novel or natural sweeteners (e.g stevia, monk fruit). Key factors driving the industry growth are the changing consumer preference for healthier and low-calorie foods which do not increase blood sugar and contain low or no calories reducing the risk of obesity related lifestyle disorders such as diabetes and cardiovascular diseases. There is also a market for direct sugar replacement with high fructose corn syrup due to its lower costs, better stability, and its availability in liquid form which makes it a preferred choice in processed foods (https://www.fortunebusinessinsights.com/high-fructose-corn-syrup-market-103273). There is no ideal sweetener for all applications and use varies widely by geography and application type. A number of widely used sugar substitutes have been linked to health concerns including increased blood sugar levels and the risk of diabetes (sucralose and saccharin https://www.diabetes.co.uk/news/2022/aug/popular-artificial-sweeteners-found-to-raise-blood-sugar.html), cellular DNA damage (sucralose: see Common artificial sweetener may cause DNA damage, cancer (medicalnewstoday.com), and as possible carcinogens (aspartame: https://www.bbc.co.uk/news/health-66057216).This suggests there is an unmet market need for a safe, low calorie, healthy alternative to sugar and sugar substitutes. The SweetBiotix® product portfolio has been developed to meet that need.Meeting the market needOptiBiotix has developed a portfolio of novel, patented, zero or low calorie sweet dietary fibres, called SweetBiotix®. They are unique in that they do not have the health concerns associated with sugar, corn syrup, or sweeteners and importantly, from a health and nutritional labelling perspective, are classified as dietary fibres. In addition to the benefits of increasing fibre intake, SweetBiotix® fibres have been shown to have a prebiotic effect (RNS: 20.02.19) by increasing the production of short chain fatty acids ("SCFA"). SCFAs are widely known for their importance in gut health, immunity and how energy is metabolised in the body and are one of the main ways in which the gut microbiome contributes to better health. This creates a clear differentiator to other products on the market and an opportunity to replace unhealthy sugars with healthy fibres in a range of food and beverage products and as an ingredient in its own right.The SweetBiotix® portfolio contains a range of products which human studies have shown have high (240X the sweetness of sugar) to moderate levels of sweetness (3X) to meet the needs of a wide range of application including fizzy drinks, snacks, bakery products, dairy products and cereals. As a general guide, the high-level sweet products could be considered a replacement for existing sweeteners whilst the moderate level sweetness products as bulk sugar replacement products. The strategy is designed to create multiple opportunities which offer added value and use for a wide range of product applications. Whist taking longer, this reduces the commercial risk which would exist with a single product approach whilst increasing the scale of the opportunity. Product developmentsOptiBiotix's products are differentiated from other natural sweeteners and sugar substitutes on the market in that they have been developed: - i. To be classified on packaging as dietary fibres providing no contribution to sugar intake and enhancing product nutritional labels.ii. Have a low glycemic index (reducing the risk of developing diabetes).iii. Enhance the gut microbiome providing additional potential health benefits.iv. Have intense sweetness (High Intensity Sweeteners) or sweetness similar to sugar (depending on product). The Company is not aware from patent searches and partner meetings of any other products currently available which have these characteristics. Partner agreementsThe Company has been working with a wide range of industry partners since 2020 and has Material Transfer Agreements ("MTA"), and/or Non-Disclosure Agreements ("NDA"), and/or Open innovation arrangements with well-known consumer brands like Kellogg's, Nestle, Coca Cola, Cargill and more specialised sweetener and fibre groups like Tereos, Givaudan, Sudzucker, Puratos and Firmench. These agreements allow us to share information and products whilst protecting our intellectual property and partners to receive information and different SweetBiotix® products to test within their product ranges. This allows them to assess texture, taste, stability, and how they would incorporate Sweetbiotix® into their product manufacturing processes. We developed SweetBiotix® in the laboratory and have been working on novel methods to scale up the manufacturing process to produce at industrial scale to supply large partners whilst having the same structural, prebiotic function, and taste and texture. We have been doing this through two different agreements for two different types of SweetBiotix®. These are:- 1. A manufacturing agreement signed with a US partner in September 2020. They are paying OptiBiotix a six figure annual milestone in H2 every year during scale up plus a six figure launch milestone payment with royalties of 5% on all sales and a further 5% on sales to 11 named companies (Kelloggs, Nestle, Coca Cola , Firmenich, Tereos, Cargill, Arla ,Tate and Lyle, Agropur, Givaudan, Tata) reflecting the development work ongoing with these partners before we signed the agreement. 2. An agreement was signed with Firmenich in July 2022 to optimise scale up and development of another type of SweetBiotix®. They will pay OptiBiotix a six figure payment per market approval (USA/Europe/Asia) plus royalties and additional milestones on sales. As previously disclosed, Firmenich are one of the world leaders in taste and the world's largest stevia supplier. Their turnover is around £3.6bn per year which has risen to US $11.4bn annual turnover following their merger with DSM, and are now known as DSM Firmenich. They are experts in their field and chose SweetBiotix® after an 18 month due diligence process. This agreement with one of the leaders in the field after extensive due diligence of the science, taste, and intellectual property, is a substantial validation of the SweetBiotix® science and commercial potential. Our products are also tested by different academic groups providing an independent assessment of their taste and prebiotic functionality. The most recent peer reviewed publication (see Prebiotic Potential of a New Sweetener Based on Galactooligosaccharides and Modified Mogrosides - PubMed (nih.gov)) in a respected industry journal concluded 'These substrates could be considered as novel candidate prebiotic sweeteners, foreseeing a feasible and innovative approach targeting the sucrose content reduction in food. This new ingredient could provide health benefits when evaluated in human studies by combining sweetness and prebiotic fibre functionality'.The combination of a major industry partner with specialist expertise investing in manufacturing scale up and verification of novelty and health potential in a number of academic publications should give investors confidence in the science and potential of the SweetBiotix® product range. Current positionBoth product types are at the end stage of manufacturing scale up with ongoing testing of samples with both partners. This is a complex and rigorous process. Typically, global partners with established brands require confirmation of a robust supply chain for all ingredients (ethically and responsibly sourced) from two different suppliers, low waste streams, humans studies/taste tests and structural and functional analysis on liquid and freeze-dried products from three different production runs to show there is no batch to batch variability. In addition, most require two year shelf life of SweetBiotix® as an ingredient and in their final products with no observable effect on appearance, taste, or texture or functionality. We are pleased to report significant progress by both partners in the commercial scale production of SweetBiotix®, with final product taste tested and accepted by our US partner. Liquid and freeze-dried products are undergoing independent structural analysis and expert panel taste testing to determine sweetness, off tastes, aftertastes etc when compared to sucrose and other products. This will determine the type of product suitable for each type of SweetBiotix® product and the regulatory pathway before progressing to a launch. We anticipate most results should be returned over the summer when we can start partner application development and launch plans. Stephen O'Hara, CEO of OptiBiotix, commented: "The development of a unique product concept within an industry is high risk, particularly in the food industry where you are competing in an industry dominated by a small number of large global players with demanding requirements. OptiBiotix has looked to overcome these challenges by working closely with partners during the product development process and believes it has created a product portfolio of sweet prebiotic fibres, called SweetBiotix®, which meet a large and growing unmet industry and consumer need. SweetBiotix® are unique in being classified as dietary fibres creating the opportunity to replace unhealthy calorific and cariogenic sugars with healthy fibres in a wide range of food and beverage products or as an ingredient in its own right. "With growing industry and consumer health concerns over traditional sugars and sweeteners, the approaching commercialisation of the SweetBiotix® family of products offers shareholders the potential for a significant enhancement in the value of the Company." Read Full Thread Reply
Posted at 19/5/2023 20:43 by woollworth humph just checked the price still dropping below, 10p at close, terrible stock aka SOHs gravy train, defo ult two... Wish I dumped at 15p, looks like we have another junk stock, to add to the rest. Bad news on results 5p or less imo. Half decent results doubtful 11.5p imo. Decent news 16p ish imo. Expecting the worse because of pathetic track record and the fact soh employed more staff adding to loss, rather than profit, as he boasted/stated, Read Full Thread Reply

Ultrasis share price data is direct from the London Stock Exchange

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions